
Alector Inc (ALEC) Stock Forecast & Price Target
Alector Inc (ALEC) Analyst Ratings
Bulls say
Alector Inc. is strategically targeting neurodegeneration through innovative therapies that enhance immune function in the brain, with a robust pipeline including programs such as AL137, AL050, and ADP064-ABC, which address significant indications. The company's proprietary ABC platform has demonstrated a strong ability to penetrate the central nervous system (CNS) and has shown favorable safety signals, potentially leading to significant clinical advancements. Early proof-of-concept data from these programs may present substantial upside opportunities for the company, given the increasing standardization of Alzheimer’s disease biomarkers, which could bolster the likelihood of meaningful clinical outcomes.
Bears say
Alector's stock outlook has been negatively impacted by the failure of the INFRONT-3 trial for latozinemab, which did not meet its primary endpoint and introduced additional translational biology risks. This setback raises concerns about the efficacy of Alector's therapies and underscores the inefficiencies in progranulin transport, potentially jeopardizing revenue projections for key products AL001 and AL002. Additionally, the company's reliance on successful clinical study outcomes and regulatory approvals, along with risks of delays and unexpected adverse effects, further compounds the uncertainties surrounding its financial viability.
This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.
Alector Inc (ALEC) Analyst Forecast & Price Prediction
Start investing in Alector Inc (ALEC)
Order type
Buy in
Order amount
Est. shares
0 shares